<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>36(8)</volume><submitter>Hirokami J</submitter><funding>The EU-PORIA registry was supported by a research grant from Boston Scientific.</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Real-life data on efficacy and safety of pulsed-field ablation (PFA) using the pentaspline multi-electrode catheter in symptomatic atrial fibrillation (AF) patients is still scarce.&lt;h4>Objective&lt;/h4>This study aims to assess the efficacy and safety of PFA in patients with persistent AF.&lt;h4>Methods&lt;/h4>Data from early commercial use across seven European centers were collected in a registry. To confirm the efficacy and safety of extra pulmonary vein (PV) ablation, patients were categorized into two groups: those undergoing pulmonary vein isolation (PVI) alone and those receiving additional ablation. Procedural and follow-up data were collected.&lt;h4>Results&lt;/h4>The study included 448 patients (347 PVI only, 101 PVI + α). In the PVI + α group, extra PV ablation included left</pubmed_abstract><journal>Journal of cardiovascular electrophysiology</journal><pagination>1710-1720</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12337630</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pulsed-Field Ablation for Persistent Atrial Fibrillation in EU-PORIA Registry.</pubmed_title><pmcid>PMC12337630</pmcid><pubmed_authors>Tohoku S</pubmed_authors><pubmed_authors>Adelino R</pubmed_authors><pubmed_authors>Schmidt B</pubmed_authors><pubmed_authors>Futing A</pubmed_authors><pubmed_authors>Mene R</pubmed_authors><pubmed_authors>Reinsch N</pubmed_authors><pubmed_authors>Blaauw Y</pubmed_authors><pubmed_authors>Hirokami J</pubmed_authors><pubmed_authors>Reichlin T</pubmed_authors><pubmed_authors>Ouss A</pubmed_authors><pubmed_authors>Bordignon S</pubmed_authors><pubmed_authors>van der Voort P</pubmed_authors><pubmed_authors>Ruwald MH</pubmed_authors><pubmed_authors>Roten L</pubmed_authors><pubmed_authors>Boveda S</pubmed_authors><pubmed_authors>Chun KRJ</pubmed_authors><pubmed_authors>Mulder BA</pubmed_authors><pubmed_authors>Kueffer T</pubmed_authors><pubmed_authors>Albrecht EM</pubmed_authors><pubmed_authors>Hansen J</pubmed_authors><pubmed_authors>Neven K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pulsed-Field Ablation for Persistent Atrial Fibrillation in EU-PORIA Registry.</name><description>&lt;h4>Background&lt;/h4>Real-life data on efficacy and safety of pulsed-field ablation (PFA) using the pentaspline multi-electrode catheter in symptomatic atrial fibrillation (AF) patients is still scarce.&lt;h4>Objective&lt;/h4>This study aims to assess the efficacy and safety of PFA in patients with persistent AF.&lt;h4>Methods&lt;/h4>Data from early commercial use across seven European centers were collected in a registry. To confirm the efficacy and safety of extra pulmonary vein (PV) ablation, patients were categorized into two groups: those undergoing pulmonary vein isolation (PVI) alone and those receiving additional ablation. Procedural and follow-up data were collected.&lt;h4>Results&lt;/h4>The study included 448 patients (347 PVI only, 101 PVI + α). In the PVI + α group, extra PV ablation included left</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-04-30T14:41:40.197Z</modification><creation>2026-04-07T16:03:36.263Z</creation></dates><accession>S-EPMC12337630</accession><cross_references><pubmed>40171797</pubmed><doi>10.1111/jce.16583</doi></cross_references></HashMap>